Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache
NCT ID: NCT04910477
Last Updated: 2021-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
90 participants
INTERVENTIONAL
2021-06-01
2021-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.
NCT05289323
Comparing the Effects of Ondansetron Versus Dexamethasone on the Incidence of Post-dural Puncture Headache (PDPH) , Nausea and Vomiting After Spinal Anaesthesia of Parturients Undergoing Caesarean Section
NCT05202574
Two Fluid Strategies for Prevention of Post-dural Puncture Headache
NCT03475784
Ondansetron and Dexamethasone for Prevention of PDPH, Nausea, and Vomiting
NCT07068230
Intravenous Dexmedetomidine in Cesarean Section Under Spinal Anesthesia
NCT04358367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days. Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days. Group S (patients will receive nebulization of saline placebo in 4 ml) twice daily for three days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexmedetomidine
Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
Dexmedetomidine
ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
Neostigmine/atropine
Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
Neostigmine/atropine
nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
Saline placebo
Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
Saline placebo
nebulization of saline placebo in 4 ml) twice daily for three days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
Neostigmine/atropine
nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
Saline placebo
nebulization of saline placebo in 4 ml) twice daily for three days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Overactive thyroid gland
* Myasthenia gravis
* Closed angle glaucoma
* High blood pressure and coronary artery disease.
* withdrawal of consent
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omar Makram Soliman
Lecturer of anesthesia and ICU
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Omar Soliman
Role: PRINCIPAL_INVESTIGATOR
Omar makram
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut university hospital
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17300608
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.